As of 2026-03-27, the EV/EBITDA ratio of Apyx Medical Corp (APYX) is -28.18. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Apyx's latest enterprise value is 160.62 mil USD. Apyx's TTM EBITDA according to its financial statements is -5.70 mil USD. Dividing these 2 quantities gives us the above Apyx EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 16.1x - 19.0x | 17.2x |
| Forward P/E multiples | 17.2x - 21.7x | 19.9x |
| Fair Price | (2.46) - (2.71) | (2.65) |
| Upside | -164.2% - -170.7% | -169.1% |
| Date | EV/EBITDA |
| 2026-03-24 | -28.90 |
| 2026-03-23 | -29.19 |
| 2026-03-20 | -25.59 |
| 2026-03-19 | -25.95 |
| 2026-03-18 | -26.96 |
| 2026-03-17 | -27.46 |
| 2026-03-16 | -26.96 |
| 2026-03-13 | -26.67 |
| 2026-03-12 | -26.60 |
| 2026-03-11 | -28.83 |
| 2026-03-10 | -25.38 |
| 2026-03-09 | -25.23 |
| 2026-03-06 | -23.00 |
| 2026-03-05 | -24.01 |
| 2026-03-04 | -24.30 |
| 2026-03-03 | -23.36 |
| 2026-03-02 | -24.15 |
| 2026-02-27 | -24.08 |
| 2026-02-26 | -25.74 |
| 2026-02-25 | -25.16 |
| 2026-02-24 | -26.03 |
| 2026-02-23 | -26.24 |
| 2026-02-20 | -27.75 |
| 2026-02-19 | -27.54 |
| 2026-02-18 | -28.76 |
| 2026-02-17 | -28.18 |
| 2026-02-13 | -27.32 |
| 2026-02-12 | -28.04 |
| 2026-02-11 | -28.76 |
| 2026-02-10 | -29.19 |
| 2026-02-09 | -29.91 |
| 2026-02-06 | -28.47 |
| 2026-02-05 | -28.90 |
| 2026-02-04 | -29.12 |
| 2026-02-03 | -32.14 |
| 2026-02-02 | -32.21 |
| 2026-01-30 | -29.48 |
| 2026-01-29 | -29.70 |
| 2026-01-28 | -29.41 |
| 2026-01-27 | -30.70 |
| 2026-01-26 | -28.40 |
| 2026-01-23 | -29.12 |
| 2026-01-22 | -28.98 |
| 2026-01-21 | -29.26 |
| 2026-01-20 | -28.26 |
| 2026-01-16 | -29.26 |
| 2026-01-15 | -28.54 |
| 2026-01-14 | -27.61 |
| 2026-01-13 | -28.47 |
| 2026-01-12 | -29.41 |